FDA approves Biogen's $56,000 drug for Alzheimer's
The Food and Drug Administration of the US approved on Monday Biogen Inc’s Aducanumab to treat Alzheimer’s disease amidst the controversy of its efficacy. Biogen has pr
Login
X
- New Ventures
- Market Analysis
- Emerging Markets
- Technology
- Professional Services
- Media & Entertainment
- Manufacturing & Retail
- Logistics & Supply Chain
- Healthcare & Pharmaceutical
- Financial Services
- Energy
- Autos
- Aerospace & Defense
- Work-Life Balance
- Strategic Thinking
- Productivity
- Decision Making
- Communication
- Sustainability
- Success Story
- Power Players
- Philanthropy
- People
- Innovation
- CEO Magazine
